Search Results for: Clinical Roundup
-
Latest IPO Filing Sees HCV Player Enanta Seeking $69M
Proceeds will be used to begin investigational new drug application-enabling studies and clinical trials through Phase IIa with its cyclophilin inhibitor, EDP-546, as well as to begin preclinical development of a nucleotide polymerase inhibitor and to support other research and development activities...Novartis snapped up exclusive, worldwide rights to another pipeline program, EDP-239, in February for $34.4 million up front, and up to $406 million in clinical, regulatory and commercial milestonesBy Catherine Shaffer | BioWorld Today | Thursday, November 8, 2012 -
Washington Roundup
In clinical trials, Infasurf was compared to Exosurf Neonatal, which is no longer marketed, and Survanta, over which Infasurf did not demonstrate clinical superiorityBioWorld Today | Tuesday, November 6, 2012 -
Financings Roundup
Isconova AB, of Uppsala, Sweden, carried out a fully subscribed rights issue of about SEK50 million (US$7.4 million) to finance clinical trials in-house, increase production capacity and continue research in new indications for the adjuvant Matrix M. Shareholders representing 46.3 percent committed to subscribe for their respective pro rata share of the issue, with the remainder guaranteed by a consortiumBioWorld Today | Monday, November 5, 2012 -
Provenge Sales Disappoint, but Dendreon Shows Growth
We were losing a lot of patients to these clinical trials...I'm not satisfied with this performance and not looking at clinical trials as an excuse," Johnson said...Shares of Vertex (NASDAQ:VRTX) fell $5.47 to close at $45.01.By Catherine Shaffer | BioWorld Today | Monday, November 5, 2012 -
Supremes to Hear Arguments on 'Fraud-on-the-Market' Claims
They also identified differences in the toxic capabilities of three drugs in this class that are currently being investigated in clinical trials...The study, by scientists at the National Cancer Institute, and colleagues, appeared in Cancer Research.By Marie Powers | BioWorld Today | Monday, November 5, 2012 -
Earnings Roundup
The future growth of United's PAH franchise hit a snag late last month when its oral treprostinil candidate earned a complete response letter, with the FDA citing issues in the product's clinical data packageBioWorld Today | Friday, November 2, 2012 -
Financings Roundup
The funds will give the company enough runway to advance investigational lupus drug RSLV-132 into clinical trials, expected to begin in mid-2013BioWorld Today | Friday, November 2, 2012 -
Financings Roundup
Integra focuses on biotech firms with products mostly in clinical developmentBioWorld Today | Thursday, November 1, 2012 -
Clinic Roundup
EnVivo Pharmaceuticals Inc., of Watertown, Mass., said data from its Phase IIb study of EVP-6124, an alpha-7 agonist, in Alzheimer's disease met both of the trial's primary endpoints, with statistically significant positive effects on cognition (p = 0.0189), as measured by ADAS-COG-13, and clinical function (p = 0.0253), as measured by the Clinical Dementia Rating Scale Sum of Boxes...Data also showed statistically significant results across several secondary endpoints of other cognitive andBioWorld Today | Thursday, November 1, 2012 -
Clinic Roundup
Muscle strength, clinical function and patient-reported outcomes also will be evaluated, though the study is not powered for those endpoints...two dose levels of active drug at four clinical sites in the U.SBioWorld Today | Wednesday, October 31, 2012 -
Clinic Roundup
Cellceutix Corp., of Beverly, Mass., said it has recruited the first patients with advanced solid tumors for clinical studies of cancer candidate KevetrinBioWorld Today | Tuesday, October 30, 2012 -
Clinic Roundup
Hadasit Bio-Holdings Ltd., of Jerusalem, said portfolio company Enlivex completed a 13-patient clinical trial of cellular treatment ApoCell for graft-vs.-host disease (GvHD), with results indicating efficacy and safety in recipients of bone marrow transplants from foreign donors...The primary endpoint of the 33-patient study is to determine the clinical benefit rate, while secondary objectives include progression-free survival and safety and tolerabilityBioWorld Today | Thursday, October 25, 2012 -
Bringing RNA Back, Mirna Gets $34.5M in Series C
Mirna will be the first company in clinical trials with a miRNA replacement therapy, and that fresh and different approach may have helped the company to attract its large, deep-pocketed investors...Shares of XOMA (NASDAQ:XOMA) fell 23 cents, to close at $2.99 Wednesday.By Catherine Shaffer | BioWorld Today | Thursday, October 25, 2012 -
Financings Roundup
The funds were raised from accredited investors and will be used to advance multiple clinical development programsBioWorld Today | Tuesday, October 23, 2012 -
Cat on a Hot Twin Proof? After Cougar, Puma Roars
The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.By Randy Osborne | BioWorld Today | Monday, October 22, 2012 -
Financings Roundup
Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities...Net proceeds are expected to total $19.3 million and will be used for ongoing clinical development of dendritic cell-based vaccine ICT-107 and for general corporate purposesBioWorld Today | Friday, October 19, 2012 -
Pharma: Clinic Roundup
Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase IIb study testing Stelara (ustekinumab) in moderate to severe Crohn's disease showed that, among patients who had previously failed or were intolerant to at least one tumor necrosis factor antagonist, a significantly greater proportion receiving intravenous Stelara achieved the primary endpoint of clinical response at week six, defined as a 100-point reduction in Crohn's Disease Activity IndexBioWorld Today | Friday, October 19, 2012 -
Clinic Roundup
The study showed that the drug was safe and well tolerated at all dose levels, and that more patients in the higher-dose cohorts showed improvement in their clinical disease activity index than patients in the lower-dose or placebo cohortsBioWorld Today | Friday, October 19, 2012 -
Cebix Closes $30.9M Series B, Reports Phase II Ersatta Data
The investors were very enthusiastic about the results from the Phase I/II clinical trial...APIM Therapeutics A/S, of Trondheim, Norway, closed a financing round to fund ATX-101, its lead compound, toward clinical trials...Proceeds would be used for R&D activities, clinical trials, investment in capital equipment and for working capital and other general corporate purposesBy Catherine Shaffer | BioWorld Today | Thursday, October 18, 2012 -
Kythera, Intercept Dazzle with Dueling Initial Public Offerings
Intercept estimated that remaining clinical development for OCA for PBC will take about $40 million, and that the current offering, plus $29.8 million from its recent Series C financing, plus its cash will be enough to put it over the top. (See BioWorld Today, Sept. 6, 2012.) That clinical development includes completion of the POISE trial and initiation of its long-term safety extension, initiation of a Phase III outcomes trial, carcinogenicity studies in animals, a Phase I safety trial inBy Catherine Shaffer | BioWorld Today | Friday, October 12, 2012
Category
Current Filters
- xNOT San Diego
Related Keywords
Categories
- x BioWorld Today (1742)
- x BioWorld International (51)
- x Bio Perspectives (3)
- x State of the Industry Report (2)
- x BioWorld Insight (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.